Page History
...
The concept map below describes the modeling discrepancies between tumor and non-tumor lesions. Note the dotted lines and boxes indicate a step that didn't happen and data not modeled.
| Excerpt Include | ||||
|---|---|---|---|---|
|
Agreed Approaches so Far
- Imaging location should be treated as the TEST Location when identifying the location of a suspected object.
- We will not make changes to the tumor findings modeling in TU, several cancer TAUGs have been published and we do not want to cause backward compatibility issues. We will only update the non-tumor lesions side.
Domain Level Questions
- If all I need to do is to identify an object, it’s location, and then evaluate its severity, no disease response to treatment data, in other words I have TU and CC data, but no TR and RS, can I use TU? Show this example: https://wiki.cdisc.org/x/zxMiBw
- How do we modeling Result Location, when the result itself is the location? Should this be modeled in variables (RESLOC), or should we create tests for result location findings?
- For tumor findings, it is recommended that "The TR domain does not include anatomical location information of each measurement record, this information can be found in the TU domain." - This works for tumor, but it is a bit odd for non-tumor lesions, show example, case 1 tr.xpt.
CT Questions - The Non-Tumor Lesion Side
...
Overview
Content Tools